Working papers

Greenblatt, Wesley H., Suman K. Maity, Roger P. Levy, and Pierre Azoulay. 2022. Does Grant Peer Review Penalize Scientific Risk Taking? Evidence from the NIH.

Greenblatt, Wesley H., Charu N. Gupta, and Jennifer Kao. 2022. Drug Repurposing During the COVID-19 Pandemic: Lessons for Expediting Drug Development and Access. (Revise and resubmit)

Greenblatt, Wesley H. 2021. Anchoring Exploration: Knowledge Certification and the Dynamics of Innovation.


Management and economics publications

Azoulay, Pierre, Wesley H. Greenblatt, and Misty L. Heggeness. 2021. Long-term Effects from Early Exposure to Research: Evidence from the NIH "Yellow Berets." Research Policy, 50(9):104332.

Greenblatt, Wesley H. 2021. Proportion, Type and Characteristics of Physician Entrepreneurship in Massachusetts. JAMA Network Open, 4(1):e2026938.


Other publications

Rubenstein, Eric M., Stefan G. Kreft, Wesley Greenblatt, Robert Swanson, and Mark Hochstrasser. 2012. Aberrant substrate engagement of the ER translocon triggers degradation by the Hrd1 ubiquitin ligase. Journal of Cell Biology, 197(6):761-773.

Greenblatt, Wesley H., Chin Hur, Amy B. Knudsen, John A. Evans, Daniel C. Chung, and G. Scott Gazelle. 2009. Cost-Effectiveness of Prophylactic Surgery for Duodenal Cancer in Familial Adenomatous Polyposis. Cancer Epidemiology, Biomarkers and Prevention, 18(10):2677-2684.